SCHEDULE: Frazier Life Sciences Amends Mereo BioPharma Stake
Beneficial Ownership Amendment
Frazier Life Sciences funds updated their beneficial ownership in Mereo BioPharma Group plc, clarifying share attribution and aggregate holdings.
Summary
- Frazier Life Sciences Public Fund, L.P. (FLSPF) beneficially owns 32,430,690 Ordinary Shares, representing 4.1% of Mereo BioPharma Group plc's outstanding shares.
- Frazier Life Sciences Public Overage Fund, L.P. (FLSPOF) beneficially owns 8,941,155 Ordinary Shares, representing 1.1% of outstanding shares.
- Frazier Life Sciences X, L.P. (FLS X) beneficially owns 1,763,230 Ordinary Shares, representing 0.2% of outstanding shares.
- Frazier Life Sciences XI, L.P. (FLS XI) beneficially owns 4,065,485 Ordinary Shares, representing 0.5% of outstanding shares.
- The aggregate beneficial ownership by the Frazier Life Sciences group totals 47,200,560 Ordinary Shares, which represents approximately 5.9% of the 795,001,444 Ordinary Shares outstanding as of May 12, 2025.
- The filing clarifies that certain individual members of investment committees (Albert Cha, James Brush, Daniel Estes) are not attributed beneficial ownership of the securities held by FLSPF, FLSPOF, and FLS XI, correcting previous overstatements.
Sentiment
Score: 5
Explanation: A routine regulatory filing clarifying beneficial ownership, with no direct positive or negative operational implications for the issuer.
Positives
- Enhanced transparency regarding the beneficial ownership structure of a significant shareholder group.
- Correction of previous beneficial ownership attribution provides clearer insight into control.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Beneficial Ownership Attribution Clarification | The filing explicitly corrects previous attribution of beneficial ownership to certain individual members of investment committees (Albert Cha, James Brush, Daniel Estes), stating they are not attributed beneficial ownership of shares held by specific Frazier funds (FLSPF, FLSPOF, FLS XI). This enhances transparency regarding the actual control persons. | 06/30/2025 | Improves clarity on the beneficial ownership structure, which is a key aspect of corporate governance and understanding shareholder control. |
Stakeholder Impact
- Clarifies the ownership structure for shareholders and the broader market, enhancing transparency regarding significant holders and their attributed control.
Key Dates
| Date | Description |
|---|---|
| 05/12/2025 | Date on which 795,001,444 Ordinary Shares were outstanding, used for percentage calculation. |
| 06/30/2025 | Date of event which required filing of this statement. |
| 08/14/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Mereo BioPharma, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, SEC Filing, Biotechnology, Pharmaceuticals, Investment Fund, Ordinary Shares, American Depository Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.